PDS Biotechnology Corp. PDSB 深 沪
等待开盘 06-19 09:30:00 美东时间
0.955
+0.046
+5.04%
华盛通- 最 高1.55
- 今 开0.92
- 成交量 42.48万股
- 最 低 0.8657
- 昨 收 0.9092
- 总市值 2.72万
- 52周最高 1.55
- 市盈率 静 --
- 换手率 1493.24%
- 52周最低 0.5068
- 委 比 -76.92%
- 总股本 2.85万
- 历史最高 17.85
- 量 比 0
- 振 幅 75.26%
- 历史最低 0.5068
- 每 手 1
- 风险率 0.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多PDS Biotechnology Establishes Up To $50M At-The-Market Common Stock Offering Program
Up to $50,000,000 Common StockWe have entered into the sales agreement (the "Sales Agreement") with Yorkville Securities, LLC ("Yorkville Securities") and B. Riley Securities, Inc. ("B. Riley Securities"; each of
06-16 04:38
Earnings Scheduled For March 30, 2026
Companies Reporting Before The Bell • Liberty All Star Equity (NYSE:USA) is est...
03-30 19:11
PDS Biotechnology Corp Reported FY25 EPS Loss Of $0.74/Share, Cash Balance Of $26.7M
Full Year 2025 Financial ResultsNet loss for the year ended December 31, 2025, was approximately $34.5 million, or $0.74 per basic and diluted share, compared to a net loss of $37.6 million, or $1.03 per basic and
03-30 19:08
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
2025-11-13 19:11
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC
A webinar on June 17, 2025, will discuss the evolving landscape of HPV16-positive HNSCC, treatment challenges, and the Merck KN-689 study, featuring experts Kevin Harrington and Katharine Price. It will also review Versamune® HPV, an investigational immunotherapy for R/M HPV16+ HNSCC, and distinguish HPV-positive and HPV-negative HNSCC as distinct diseases.
2025-06-09 12:00
HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $21 price target.
2024-09-17 18:42
PDS Biotech To Present Updated VERSATILE-002 Data At ESMO Congress 2024
PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious
2024-09-09 20:19
Alliance Global Partners Maintains Buy on PDS Biotechnology, Raises Price Target to $7
Alliance Global Partners maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and raises the price target from $5 to $7.
2024-08-21 00:08
